Retatrutide

Extracted Attributes

• Developer

  Eli Lilly and Company

• Half-life

  Approximately 6 days

• Current Status

  Investigational (Phase III Clinical Trials)

• Alternative Name

  LY-3437943

• Synthesis Method

  Solid-phase peptide synthesis (SPPS)

• Clinical Efficacy

  15% to 24% body weight reduction over 48-72 weeks

• Mechanism of Action

  Triple agonist targeting GLP-1, GIP, and GCGR receptors

• Primary Indications

  Obesity and Type 2 Diabetes Mellitus (T2DM)

• Administration Route

  Once-weekly subcutaneous injection

Timeline

• Phase 2 trial results published in the New England Journal of Medicine (NEJM) showing significant weight reduction in adults with obesity. (Source: NEJM)

  2023-06-26

• Ongoing Phase III clinical trials, including the TRIUMPH study program, to evaluate long-term safety and efficacy. (Source: PMC)

  2024-01-01

• Projected year for potential FDA approval based on current clinical trial trajectories. (Source: JoinMidi)

  2026-12-31

Retatrutide

Retatrutide (LY-3437943) is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors).

Web Search Results

• Retatrutide - Wikipedia

  Retatrutide (LY-3437943) is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors). ## Mechanism of action [edit] GLP-1 receptors improve insulin sensitivity and increase satiety. Retatrutide has shown to increase insulin secretion. Furthermore, agonism of the glucagon receptor increases energy expenditure and promotes fat loss and metabolic activity. With current research, activation of these receptors has overall reduced caloric intake and increased energy expenditure, successfully leading to higher weight loss compared to alternative treatments. ## Adverse effects [edit] [...] Retatrutide is synthetically engineered and produced using solid-phase peptide synthesis (SPPS). This is when amino acids are added to a peptide chain and attached to solid resin forming a backbone. After the backbone is synthesized, the molecule is cleaved chemically, then purified. Lipidation modifications also occur, meaning a fatty-acid side chain is added to promote reversible binding to albumin. This modification allows for a longer drug half-life, raising compliance as it enables once-weekly dosing. ## Research [edit] [...] Systematic reviews and meta-analyses of randomized controlled trials report that retatrutide produces substantial reductions in body weight in adults with obesity, with mean percentage weight loss typically between 15 and 24 percent over 48 to 72 weeks, depending on study protocols and populations. Adverse events are most commonly gastrointestinal symptoms such as nausea and diarrhea, with relatively low rates of study discontinuation and infrequent serious adverse events reported during trials. Safety assessments also indicate a low risk of hypoglycemia and no significant elevation in cardiovascular or hepatic adverse events in non-diabetic populations across published studies. ## Chemistry [edit] Retatrutide is a peptide with the following amino acid sequence

• Triple–Hormone-Receptor Agonist Retatrutide for Obesity

  Retatrutide (LY3437943; Eli Lilly) is a single peptide conjugated to a fatty diacid moiety and has agonism toward the GIP, GLP-1, and GCG receptors. As compared with the endogenous receptor ligands, retatrutide is less potent at the human GCG and GLP-1 receptors (by a factor of 0.3 and 0.4, respectively) and is more potent at the human GIP receptor (by a factor of 8.9).12 The pharmacokinetics of retatrutide are considered dose-proportional; it has a half-life of approximately 6 days,13 which enables weekly administration. In a phase 1b trial involving participants with type 2 diabetes, treatment with retatrutide resulted in a placebo-adjusted least-squares mean weight reduction of 8.96 kg (approximately 10%) in the highest-dose (12-mg) group after 12 weeks.13 In the phase 2 trial

• Retatrutide—A Game Changer in Obesity Pharmacotherapy - PMC

  ## are global health crises with significant morbidity and mortality. Retatrutide, a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors, represents a groundbreaking advancement in obesity and T2DM pharmacotherapy. This review synthesizes findings from preclinical and clinical studies, highlighting retatrutide’s mechanisms, efficacy, and safety profile. Retatrutide’s unique molecular structure enables potent activation of GLP-1, GIP, and glucagon receptors, leading to significant weight reduction, improved glycemic control, and favorable metabolic outcomes. Animal studies demonstrate retatrutide’s ability to delay gastric emptying, reduce food intake, and promote weight loss, with superior [...] Retatrutide develops in a single continuous helical structure that allows it to run through the receptor’s transmembrane domain with its N-terminal segment. The C-terminal segment takes part in interactions with the N-terminal α-helix of the extracellular domain, the extracellular tip of the transmembrane helix 1 of the GLP-1 receptor, and the extracellular loop 1 of the GIP receptor. This molecule is more potent at the human GIP receptor (EC 50: 0.0643 nM) and less potent at the GLP-1 (EC 50: 0.775 nM) and glucagon (EC 50: 5.79 nM) receptors . It has a dose-dependent action and causes a decrease in gastric emptying, while with a half-life of 6 days, it can mostly be used on a weekly basis. Retatrutide shows mostly hepatic metabolism but does not interact with cytochrome P450 enzymes . [...] reduce food intake, and promote weight loss, with superior efficacy compared to other incretin-based therapies. Phase I and II clinical trials corroborate these findings, showing dose-dependent weight loss, reductions in Glycated Hemoglobin (HbA1c) levels, and improvements in liver steatosis and diabetic kidney disease. Common adverse effects are primarily gastrointestinal and dose-related. Ongoing Phase III trials, such as the TRIUMPH studies, aim to further evaluate retatrutide’s long-term safety and efficacy in diverse patient populations. While retatrutide shows immense promise, considerations regarding cost and the quality of weight loss beyond BMI reduction warrant further investigation. Retatrutide heralds a new era in obesity and T2DM treatment, offering hope for improved patient

• How To Get Retatrutide with a Clinical Trial

  Retatrutide is an investigational weight-loss drug showing strong results in trials, but it is not FDA-approved yet. Approval is expected in 2026. Retratrutide has shown even greater percentage weight loss than other medications in this category and may be an option for those few who did not fully respond or have plateaued on their weight loss from other medications. Currently, the only safe and legal way to access retatrutide is through a clinical trial like those listed on clinicaltrials.gov. Any website or individual claiming to sell retatrutide outside of a trial is not doing so legally or compliant with safety processes and regulations. [...] IN THIS ARTICLE How to Get Retatrutide Why Retatrutide May Help With Menopausal Weight Gain Retatrutide Alternatives for Weight Loss ## What Is Retatrutide? Similar to other GLP-1 medications, retatrutide is an injectable medication that targets hormone receptors in your body that directly impact metabolism and appetite. Retatrutide targets three different receptors: GLP-1 (helps regulate appetite and blood sugar) GIP (supports insulin response) Glucagon (affects energy use and fat metabolism) By targeting all three, the medication delays how fast your stomach digests food, lowers your appetite, and ultimately reduces how much food you eat.This can lead to numerous improvements in health, including: [...] Retatrutide and tirzepatide are often compared because they represent the next wave of metabolic medications, but they’re not equally accessible. Tirzepatide is FDA-approved (for diabetes and weight loss, depending on the brand) and works as a dual-agonist, targeting GLP-1 and GIP receptors to reduce appetite, improve insulin response, and support weight loss. Retatrutide, by contrast, is still investigational and only available through clinical trials. It goes one step further as a triple-agonist, targeting GLP-1, GIP, _and_ glucagon receptors, which may enhance fat metabolism. Early trial data suggest retatrutide could lead to greater average weight loss than tirzepatide, but its long-term safety, side effects, and real-world tolerability are still being studied.

• Retatrutide Side Effects and Safety: What We Know

  Retatrutide is shaping up to be one of the most promising next-generation weight loss medications, with early results that go beyond what we’ve seen from current GLP-1 and dual agonist options. Its triple-action approach—targeting appetite, digestion, and energy expenditure at the same time—helps explain why the weight loss numbers are so striking. But as with any powerful medication, that added effectiveness comes with trade-offs. The side effects look familiar in many ways, especially gastrointestinal symptoms, but there are also a few signals—like changes in heart rate—that researchers are still watching closely. [...] Injection, Dynamite, Weapon What you’ll learn: You’ve probably been hearing more about retatrutide lately as a powerful weight loss medication that can rival the GLP-1s currently available. Developed by Eli Lilly, the same company that produces Zepbound® and Mounjaro®, retatrutide is an investigational once-weekly injection still in testing. Were it to be approved, it would be the first medication to activate three metabolic hormone receptors at once—GLP-1, GIP, and glucagon. If you are familiar with tirzepatide, the active ingredient in Zepbound®, it activates GLP-1 and GIP.